The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma

xlomafota13 shared this article with you from Inoreader The Role of Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma Via Otolaryngologic Clinics of North America Systemic therapy for patients with head and neck cutaneous squamous cell carcinoma (HNCSCC) generally is used for patients with advanced disease and most often employed for patients in the palliative setting when disease is unresectable and/or widely metastatic. Cytotoxic agents and epidermal growth factor receptor pathway targeted therapy have been utilized most commonly, with few clinical data to support their efficacy. Adjuvant postoperative chemoradiation with platinum has been called into question based on recent data. Programmed cell death protein 1 receptor immune checkpoint inhibitors have demonstrated profound activity in HNCSCC, and cemiplimab and pembrolizumab now are approved for use for unresectable/metastatic disease. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.